# NAD+ Research: The Human Trial and Mechanism Literature > NAD+ research, layered: the redox-and-signaling mechanism, the randomized precursor trials that raised blood NAD+, and the thin injectable evidence. Every quantitative claim cited. How NAD+ works in the cell, what the precursor RCTs measured, and where the evidence thins — read in strata from the best-supported finding to the open gap. ## The short version This page collects the NAD+ research in layers. At the bottom is the mechanism: NAD+ (a fuel-handling helper molecule every cell uses) shuttles electrons to make energy and feeds the cell's repair-and-signaling enzymes. In the middle are the randomized trials of oral precursors (building blocks the body converts into NAD+ — NMN and NR), which reliably raise the NAD+ measured in blood. At the front is the most-replicated result: those blood-NAD+ increases. Furthest back, in honest haze, is the unproven part — whether raising blood NAD+ changes hard health outcomes in people. We label each layer for what it is. ## How NAD+ works: redox carrier and signaling substrate NAD+ does two jobs. As a redox carrier it cycles between an oxidized form (NAD+) and a reduced form (NADH), accepting electrons in glycolysis and the TCA cycle and donating them in the mitochondrial electron transport chain to drive ATP synthesis [5]. The ratio between the two forms — the NAD+/NADH redox couple — is itself a metabolic signal, reporting how oxidized or reduced the cell's energy state is at any moment. As a signaling substrate NAD+ is consumed — not just recycled — by three enzyme families: sirtuins (NAD+-dependent enzymes that regulate metabolism and DNA repair), PARPs (DNA-damage repair enzymes, chiefly PARP1) and CD38 (an NAD+-consuming ectoenzyme) [5]. Each of these spends NAD+ rather than merely borrowing it, which couples the size of the NAD+ pool directly to the cell's capacity for DNA repair, deacylation signaling and immune regulation. When DNA damage activates PARP1, for instance, it can draw down NAD+ sharply. Because those enzymes spend NAD+, the cell must constantly remake it. The dominant route in mammals is the salvage pathway, which recycles nicotinamide back into NAD+ through the rate-limiting enzyme NAMPT [5]. NAMPT expression is induced by exercise and follows a circadian rhythm, tying NAD+ supply to activity and time of day. In cultured and intact mouse skeletal muscle, knocking down NAMPT lowered NAD+ and impaired maximal respiratory capacity, while the precursor nicotinamide riboside restored NAD+ and respiration [15] — direct evidence that NAD+ salvage is required for mitochondrial function. ## Why NAD+ falls with age Tissue NAD+ declines across the lifespan, and a principal cause is rising consumption. CD38 activity increases with age and inflammation; in mice, CD38 deletion preserved NAD+ levels and SIRT3 activity and protected mitochondrial and metabolic health into older age [2]. The mechanism connects NAD+ loss to inflammaging: inflammatory factors secreted by senescent cells — the senescence-associated secretory phenotype — activate CD38-bearing macrophages, which then consume more NAD+, a feed-forward loop the CD38 study helped establish [2]. A foundational review frames the age-related fall as competition among the NAD+-consuming enzymes — sirtuins, PARPs and CD38 — for a shrinking pool, and positions restoring NAD+ as a candidate strategy against age-related decline [5]. One proposed downstream consequence is pseudohypoxia, a disruption of nuclear-mitochondrial communication that low NAD+ can produce even when oxygen is adequate, linking the coenzyme's decline to mitochondrial dysfunction [5]. Human observational data align with the mechanism. In muscle biopsies from 119 older men across three populations, sarcopenia tracked with a transcriptional signature of mitochondrial bioenergetic dysfunction, fewer mitochondria and low NAD+ through perturbed biosynthesis and salvage [13]. That the same NAD+-depletion signature appears across ethnicities strengthens the case that the decline is a general feature of human aging, not a quirk of one population. ## NAD supplement research: what the trials actually measured The NAD supplement literature is, in practice, a precursor literature — because oral NAD+ itself is poorly absorbed, the controlled human trials studied NMN, NR and nicotinamide. Their most consistent, best-replicated endpoint is whole-blood NAD+, the standard pharmacodynamic readout (direct tissue NAD+ sampling in humans is invasive and rare). That readout moves reliably. NR at 100/300/1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%/51%/142% [4]; a single 1000 mg NR dose raised NAD+ roughly 2.7-fold over 24 hours [6]; 1000 mg/day NR for 6 weeks raised it about 60% [7]. NMN at 300-900 mg/day raised blood NAD+ significantly versus placebo across a 60-day multicenter trial [3]. The result generalizes across precursor, dose and study population: raising blood NAD+ with an oral precursor is a settled pharmacodynamic fact. What it produces downstream is the open question of the next section. ## Reported outcomes in the research literature Beyond raising NAD+, several trials measured functional NAD+ benefits, with mixed and generally preliminary results. Ten weeks of NMN at 250 mg/day improved muscle insulin sensitivity (by hyperinsulinemic-euglycemic clamp) in prediabetic, postmenopausal women, without changing body composition or HbA1c [1]. Twelve weeks of NMN at 250 mg/day raised ventilatory thresholds during incremental treadmill testing in amateur runners, interpreted as improved skeletal-muscle oxygen utilization [10]. The 60-day NMN trial reported improved walking distance and quality-of-life scores alongside the blood-NAD+ rise [3]. NR's randomized crossover showed a trend toward reduced aortic stiffness and lower systolic blood pressure, not a definitive effect [7]. Preclinical signals are broader. In a mouse mitochondrial-myopathy model, NR restored muscle and liver NAD+ and was associated with greater exercise capacity [12]; in reproductively aged mice, an AI radiomic analysis classified 60% of NMN-treated aged oocytes as having a "young" morphology [11]. These are animal findings; no human trial establishes such outcomes. ## Injectable and IV NAD+: the published pharmacokinetic and tolerability data Injectable NAD+ — the marketed NAD injection — bypasses oral absorption but carries the weakest controlled evidence of any route. A human pharmacokinetic pilot using a continuous intravenous infusion found NAD+ is extensively metabolized extracellularly and rapidly cleared from plasma, with near-complete plasma removal within roughly the first two hours of infusion [9]. Reported wellness-clinic infusion protocols run roughly 250-1000 mg per session over several hours. Tolerability data note that infusions can cause chest tightness, abdominal discomfort, flushing and nausea if run too fast, with symptoms resolving on completion. A distinct safety concern is product quality: a compounded injectable NAD+ has been subject to an FDA Class I recall for elevated bacterial endotoxin. IV NAD+ is therefore presented here as an unapproved compounded therapy with documented quality risks and thin efficacy data — never as an approved treatment. ## What controlled studies say about IV NAD+ therapy Controlled evidence for IV NAD+ therapy is limited and mostly pilot or retrospective. The clearest controlled datum is pharmacokinetic, not clinical: infused NAD+ is rapidly cleared and heavily metabolized before cells take it up [9]. Historical and small pilot reports describe cognitive or addiction-related changes, but rigorous randomized trials are lacking, so the route's clinical claims rest on far weaker ground than the oral precursor RCTs. ## Where the evidence stands Read in layers, the NAD+ literature has a firm base and an unsettled top. The base is mechanism and pharmacodynamics: NAD+ is a central redox and signaling coenzyme [5], it declines with age partly through CD38 [2], and oral precursors raise whole-blood NAD+ dose-dependently and reproducibly across trials [4][3][6][7]. That much is well established. The unsettled part is clinical translation. Some trials report functional gains — muscle insulin sensitivity [1], aerobic capacity [10], physical performance [8] — but the effects are modest, not always replicated, and concentrated in specific populations. The most current authoritative synthesis, a 2025 Nature Metabolism review, concluded that human efficacy data remain limited, that age-related NAD+ decline has been documented consistently in only a limited number of human studies, and that tissue-specific NAD+ data are sparse [16]. The honest reading: raising blood NAD+ is proven; what raising it does for human health is still being measured, and rodent results should not be read as human conclusions. --- The NAD+ literature read in strata — the coenzyme at the base, its oral precursors above, and the blood-NAD+ the trials measured at the front — cited to source, with nothing here prescribed, dispensed, or sold.